MMorgan Stanley AAMD · AMD

Morgan Stanley Raises AMD Price Target to $465

Aug 5, 2026· 1 min read· Reproduced verbatim
Rating
Unknown
Price target
$465
Previous
$410
Implied downside
-10%

Morgan Stanley analyst Joseph Moore raised the price target on AMD (NASDAQ: AMD) to $465 (from $410) while maintaining an Equalweight rating.

“Thoughts on the stock: We can’t completely ignore the cost of the warrants. The CPU narrative is exceptional, and the Helios is likely to make inroads next year.

But the Helios success comes at a marketing expense of issuing $15 bn+ in warrants for every $15-20 bn in revenues for two customers for the foreseeable future.

If that were treated as a cash expense, it would wipe out profitability. We actually think the warrants are a good idea, and are likely to stimulate customer interest.

But issuing stock has a cost, and whatever GPU success that they achieve is clearly influenced by these deals.

That does put an asterisk next to the potential achievements in GPUs – and points to better risk/rewards for stocks that trade at a mid teens multiple on earnings that don’t have such a high contra cost.

To be clear, we aren’t objecting to the warrant issuance, but we are saying that it has a negative impact on the earnings of the company over the next 3-4 years, which makes the stock less attractive than peers that aren’t doing that.

As far as our PT, we had assumed a ~31x multiple on CY27 Modelware EPS (incl stock comp) of $13.13.

Our numbers come up to $15.09, and on the same ~31x PE, our PT comes up to $465 vs $410 previously. ~31x is a premium to large cap AI semis peers NVDA and AVGO, reflecting unique opportunities in server CPU and a potentially long runway for growth in AI.”

Disclaimer
The price target and rating on this page are the opinion of the issuing research firm and its analyst, not of Price Target. This page is published for informational purposes only and is not investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consider your own circumstances and consult a licensed financial adviser before making investment decisions.

This research note is reproduced verbatim from the issuing firm. Price Target never edits, paraphrases or alters analysts’ words — we only republish them in one place.

Share

Share on
Price Target is an archive of Wall Street analyst research, published for informational purposes only. Nothing on this site is investment advice, a recommendation, or an offer to buy or sell any security. Analyst ratings and price targets are the opinions of the issuing firms, not of Price Target. Always do your own research or consult a licensed financial adviser.